Thiard News@F4F

@newsen.bsky.social

5 days ago

Survey Reveals Most Americans Believe Chronic Diseases Are Preventable but Lack Confidence in Managing Health A new survey highlights a gap in confidence among Americans regarding health management, despite believing that chronic diseases can be prevented.

Survey Reveals Most Americans Believe Chronic Diseases Are Preventable but Lack Confidence in Managing Health #United_States #Health_Management #Abbott #Abbott_Park #Chronic_Disease

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

John Stamos and Jodie Sweetin Promote Cologuard® Screening Awareness Campaign for Colon Cancer Famous sitcom stars John Stamos and Jodie Sweetin reunite for a campaign to encourage colorectal cancer screenings. Don't miss this vital conversation.

John Stamos and Jodie Sweetin Promote Cologuard® Screening Awareness Campaign for Colon Cancer #United_States #Abbott_Park #Cologuard #John_Stamos #Jodie_Sweetin

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Abbott's Acquisition of Exact Sciences: A Game-Changer for Cancer Diagnostics Abbott's acquisition of Exact Sciences positions the company as a frontrunner in cancer diagnostics, significantly enhancing access to innovative healthcare solutions for millions.

Abbott's Acquisition of Exact Sciences: A Game-Changer for Cancer Diagnostics #United_States #Abbott #Abbott_Park #cancer_screening #Exact_Sciences

Thiard News@F4F

@newsen.bsky.social

1 month ago

Abbott Marks a Milestone with Its 409th Consecutive Quarterly Dividend Declaration Abbott continues its legacy of financial stability by declaring its 409th consecutive quarterly dividend of 63 cents per share, payable in May 2026.

Abbott Marks a Milestone with Its 409th Consecutive Quarterly Dividend Declaration #United_States #Dividend #Abbott #Abbott_Park #SP500

Thiard News@F4F

@newsen.bsky.social

2 months ago

Abbott Releases Fourth-Quarter and Full-Year 2025 Financial Results with Positive 2026 Outlook Abbott's fourth-quarter and full-year 2025 financial outcomes show growth in earnings and a robust outlook for 2026, driven by strategic acquisitions and new product approvals.

Abbott Releases Fourth-Quarter and Full-Year 2025 Financial Results with Positive 2026 Outlook #None #Abbott #Abbott_Park #2025_Earnings #Financial_Overview

Thiard News@F4F

@newsen.bsky.social

3 months ago

Abbott's Innovative Volt Pulsed Field Ablation System Gains FDA Approval for Atrial Fibrillation Treatment Abbott's Volt™ Pulsed Field Ablation System has received FDA approval, presenting a new treatment option for atrial fibrillation, facilitating better outcomes for patients.

Abbott's Innovative Volt Pulsed Field Ablation System Gains FDA Approval for Atrial Fibrillation Treatment #USA #Abbott #Abbott_Park #Atrial_Fibrillation #Volt_PFA_System

Thiard News@F4F

@newsen.bsky.social

3 months ago

Abbott's Amplatzer Piccolo Delivery System Gains FDA and CE Approval to Enhance Treatment for Preterm Infants Abbott has received FDA clearance and CE Mark for its innovative Amplatzer Piccolo Delivery System, designed to improve PDA treatment in premature infants.

Abbott's Amplatzer Piccolo Delivery System Gains FDA and CE Approval to Enhance Treatment for Preterm Infants #USA #FDA #Abbott_Park #CE_Mark #Amplatzer_Piccolo

Thiard News@F4F

@newsen.bsky.social

4 months ago

Abbott Marks 54 Consecutive Years of Dividend Increases with Recent Boost Abbott proudly announces a 6.8% increase in its quarterly dividend, achieving an impressive 54-year streak of growth and a notable 70% rise since 2020.

Abbott Marks 54 Consecutive Years of Dividend Increases with Recent Boost #United_States #dividends #Abbott #Abbott_Park #SP500

Thiard News@F4F

@newsen.bsky.social

4 months ago

Abbott's Lingo™ Expansion to Android Enhances Real-Time Glucose Monitoring Accessibility Abbott announces the expansion of its Lingo™ glucose monitoring device to Android users, enhancing the accessibility of real-time glucose data for better health decisions.

Abbott's Lingo™ Expansion to Android Enhances Real-Time Glucose Monitoring Accessibility #USA #Abbott #Abbott_Park #glucose_monitoring #Lingo

Thiard News@F4F

@newsen.bsky.social

4 months ago

Abbott Launches Innovative Protein Shakes to Support Muscle Health after Age 40 Abbott unveils two Ensure Max Protein shakes aimed at promoting muscle health among adults, with the support of former NFL MVP Matt Ryan.

Abbott Launches Innovative Protein Shakes to Support Muscle Health after Age 40 #United_States #Abbott #Abbott_Park #Ensure_Max_Protein #Matt_Ryan

Thiard News@F4F

@newsen.bsky.social

5 months ago

Abbott Reports Strong Third-Quarter Growth and Adjusts Guidance for 2025 Abbott Laboratories announces its financial results for Q3 2025, demonstrating notable sales growth and reaffirming its full-year guidance, showcasing strong market performance.

Abbott Reports Strong Third-Quarter Growth and Adjusts Guidance for 2025 #USA #Abbott_Park #Abbott_Laboratories #TriClip #Navitor

Thiard News@F4F

@newsen.bsky.social

6 months ago

Abbott Continues Legacy With the 407th Consecutive Quarterly Dividend Announcement Abbott has declared its 407th consecutive quarterly common dividend, reinforcing its commitment to shareholder returns since 1924. Join us as we explore this milestone.

Abbott Continues Legacy With the 407th Consecutive Quarterly Dividend Announcement #USA #healthcare #Dividend #Abbott #Abbott_Park

Thiard News@F4F

@newsen.bsky.social

8 months ago

Abbott's Strong Financial Performance in Second Quarter of 2025 Shows Robust Growth Prospects Abbott reported impressive financial results for Q2 2025, showcasing sales growth, EPS increase, and strategic advancements in medical technology.

Abbott's Strong Financial Performance in Second Quarter of 2025 Shows Robust Growth Prospects #United_States #financial_results #Abbott #Abbott_Park #Q2_2025

Thiard News@F4F

@newsen.bsky.social

10 months ago

Abbott's Revolutionary Tendyne Device Gains FDA Approval for Minimally Invasive Mitral Valve Replacement The FDA has approved Abbott's Tendyne device, a groundbreaking solution for mitral valve replacement that avoids the need for open-heart surgery.

Abbott's Revolutionary Tendyne Device Gains FDA Approval for Minimally Invasive Mitral Valve Replacement #United_States #Abbott #Abbott_Park #Mitral_Valve #Tendyne

Thiard News@F4F

@newsen.bsky.social

10 months ago

Abbott's Libre® Technology Revolutionizes Heart Health for Diabetic Patients by Reducing Hospitalizations Abbott's FreeStyle Libre® technology is transforming diabetes management by significantly lowering heart complication hospitalizations, enhancing patients' overall health outcomes.

Abbott's Libre® Technology Revolutionizes Heart Health for Diabetic Patients by Reducing Hospitalizations #USA #Abbott #Abbott_Park #diabetes #FreeStyle_Libre

Thiard News@F4F

@newsen.bsky.social

11 months ago

Abbott Revolutionizes Diabetes Care by Integrating Glucose Data with Epic EHR System The collaboration between Abbott and Epic enhances diabetes management by integrating real-time glucose monitoring data directly into electronic health records.

Abbott Revolutionizes Diabetes Care by Integrating Glucose Data with Epic EHR System #United_States #Abbott_Park #Epic_EHR #FreeStyle_Libre #Abbott_Diabetes

Thiard News@F4F

@newsen.bsky.social

11 months ago

Abbott's Volt™ PFA System Shows Promising 12-Month Results for AFib Patients Abbott's recent Volt CE Mark Study reveals excellent long-term safety and efficacy for the Volt PFA System treatting AFib patients, enhancing their quality of life significantly.

Abbott's Volt™ PFA System Shows Promising 12-Month Results for AFib Patients #USA #Abbott #Abbott_Park #Volt™_PFA_System #AFib

Thiard News@F4F

@newsen.bsky.social

11 months ago

Abbott's Q1 2025 Results Highlight Growth in Diverse Healthcare Sectors Abbott has revealed robust financial results for Q1 2025, showcasing continued growth across multiple sectors, reaffirming their full-year guidance.

Abbott's Q1 2025 Results Highlight Growth in Diverse Healthcare Sectors #United_States #Abbott #Abbott_Park #TriClip #Volt_PFA

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott's Volt PFA System Receives CE Mark, A New Hope for AFib Patients Abbott has gained CE Mark approval for its cutting-edge Volt™ Pulsed Field Ablation System, providing fresh treatment options for AFib patients. This advancement marks a significant leap in cardiac care.

Abbott's Volt PFA System Receives CE Mark, A New Hope for AFib Patients #USA #Abbott #Abbott_Park #Atrial_Fibrillation #Volt_PFA_System

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott's Volt™ PFA System Receives CE Mark for Heart Rhythm Disorder Treatment Abbott has achieved CE Mark approval for its Volt™ Pulsed Field Ablation System, offering a novel treatment for atrial fibrillation patients in Europe.

Abbott's Volt™ PFA System Receives CE Mark for Heart Rhythm Disorder Treatment #USA #Abbott #Abbott_Park #Atrial_Fibrillation #Volt_PFA_System

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott Launches Clinical Trial of Innovative Lithotripsy Device for Coronary Artery Disease Patients Abbott has received FDA approval for a clinical trial assessing its Intravascular Lithotripsy device aimed at treating coronary artery disease. This new technology could enhance patient outcomes significantly.

Abbott Launches Clinical Trial of Innovative Lithotripsy Device for Coronary Artery Disease Patients #United_States #Abbott #Abbott_Park #CAD #Intravascular_Lithotripsy

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott Marks a Milestone with 405 Consecutive Dividend Payments Abbott Laboratories continues its impressive streak by declaring its 405th consecutive quarterly dividend of 59 cents per share, showcasing financial stability.

Abbott Marks a Milestone with 405 Consecutive Dividend Payments #United_States #Dividend #Abbott #Abbott_Park #Financial_Growth

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott Reports Strong Fourth-Quarter and Full-Year 2024 Financial Results Along with 2025 Guidance Abbott has reported impressive financial results for Q4 and the entire year of 2024, showcasing significant growth in sales and solid projections for 2025.

Abbott Reports Strong Fourth-Quarter and Full-Year 2024 Financial Results Along with 2025 Guidance #United_States #financial_results #Abbott #Abbott_Park #earnings_report

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott's Groundbreaking Leadless Pacemaker Procedures Set New Standards in Cardiac Care Abbott has pioneered the world's first leadless pacing procedures in the heart's left bundle branch, offering new hope for those with irregular heart rhythms.

Abbott's Groundbreaking Leadless Pacemaker Procedures Set New Standards in Cardiac Care #United_States #Abbott #Abbott_Park #Leadless_Pacemaker #AVEIR_CSP

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott Celebrates 53 Years of Steady Dividend Increases with Latest Rise Abbott announces a quarterly dividend increase, marking the 53rd consecutive year of growth. The latest rise brings the payout to 59 cents per share.

Abbott Celebrates 53 Years of Steady Dividend Increases with Latest Rise #United_States #healthcare #Abbott #Abbott_Park #dividend_increase

Thiard News@F4F

@newsen.bsky.social

1 year ago

Abbott Makes Significant Progress with Innovative TAVI System for Aortic Stenosis Treatment Abbott has announced the first procedures with its new investigational TAVI system designed to combat aortic stenosis, an important heart valve disease. This development aims to enhance patient care worldwide.

Abbott Makes Significant Progress with Innovative TAVI System for Aortic Stenosis Treatment #United_States #Abbott #TAVI_System #Aortic_Stenosis #Abbott_Park